<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00956943</url>
  </required_header>
  <id_info>
    <org_study_id>809716</org_study_id>
    <secondary_id>R21DA026889</secondary_id>
    <nct_id>NCT00956943</nct_id>
  </id_info>
  <brief_title>Assessment of High Dose Transdermal Nicotine for Fast Metabolizers of Nicotine</brief_title>
  <acronym>HDP</acronym>
  <official_title>Assessment of High Dose Transdermal Nicotine for Fast Metabolizers of Nicotine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Unfortunately, the investigators still need to assess and identify novel ways to help people
      quit smoking. Differences between people in terms of how fast they metabolize nicotine
      influences response to transdermal nicotine patches, the most popular nicotine dependence
      treatment, and it affects plasma levels of nicotine from treatment. These studies suggest
      that fast metabolizers of nicotine may show better quit rates if they receive higher doses of
      transdermal nicotine. This preliminary study is designed to assess, for the first time,
      whether fast nicotine metabolizers show higher quit rates if given high dose transdermal
      nicotine, versus standard dose. The study findings may help to support a subsequent large
      trial to assess standard versus high dose transdermal nicotine for slow versus fast
      metabolizers of nicotine, which may lead to a more personalized approach to treating nicotine
      dependence using the nicotine patch to improve therapeutic benefits of transdermal nicotine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Novel approaches to treating nicotine dependence remain a priority. The transdermal nicotine
      patch is the most widely used form of tobacco dependence treatment, but only ~1 in 5 smokers
      who use this treatment achieve cessation. One factor that may contribute to a poor response
      to transdermal nicotine is inter-individual variability in the rate of nicotine metabolism,
      which can be measured in saliva by the ratio of 3'hydroxycotinine (3-HC) to its precursor
      cotinine.

      Two clinical trials with transdermal nicotine have shown that the 3-HC/cotinine ratio
      predicts response to transdermal nicotine such that faster metabolizers of nicotine (higher
      3-HC/cotinine ratios) have lower quit rates, vs. slower nicotine metabolizers. Among
      abstainers in these trials, the 3-HC/cotinine ratio also predicts therapeutic levels of
      nicotine on transdermal nicotine, with faster metabolizers of nicotine exhibiting lower
      nicotine. Thus, faster metabolizers of nicotine may require higher nicotine doses to achieve
      the same therapeutic benefit from transdermal nicotine as do slow nicotine metabolizers.

      To date, clinical trials have shown that, compared to the standard dose of transdermal
      nicotine (21mg), higher doses (42mg) have no significant effect on quit rates. However, no
      trial of high dose transdermal nicotine considered inter-individual variability in the rate
      of nicotine metabolism. Thus, as a preliminary step toward conducting a fully-powered,
      randomized clinical trial to assess standard vs. high dose transdermal nicotine for slow vs.
      fast metabolizers of nicotine, we propose to evaluate, for the first time, the efficacy of
      high-dose transdermal nicotine (vs. standard dose) among fast metabolizers of nicotine (i.e.,
      upper quartile of the 3-HC/cotinine ratio distribution).

      We chose only fast metabolizers of nicotine for this trial since: 1) slow metabolizers of
      nicotine exhibit high quit rates on standard transdermal nicotine and may experience adverse
      effects from higher doses; and 2) as a &quot;proof of concept&quot; R21 application, our primary
      objective is to test whether high doses of nicotine increase quit rates among fast
      metabolizers of nicotine. Specifically, smokers who are fast metabolizers of nicotine will
      receive counseling and will be randomized to: 1) standard (1 X 21mg patch and 1 X placebo
      patch), or 2) high dose (2 x 21mg patches) transdermal nicotine.

      The primary outcome is biochemically-verified 7-day point prevalence cessation after 8 weeks
      of treatment. Differences in patch-related side effects and mediators of transdermal nicotine
      effects (e.g., nicotine levels, withdrawal) across the study conditions will also be
      assessed.

      Ultimately, this line of research hopes to provide the evidence necessary to translate
      research on the 3-HC/cotinine ratio to clinical practice for the treatment of tobacco
      dependence. Specifically, this research may show that a measure of nicotine metabolism rate
      could be used to maximize the therapeutic benefits of transdermal nicotine by providing slow
      metabolizers of nicotine with a standard patch dose and fast metabolizers of nicotine with
      high dose transdermal nicotine. Identifying an effective treatment for faster metabolizers of
      nicotine is also critical since these individuals are at increased risk for lung cancer.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biochemically Verified 7-day Point Prevalence Abstinence at the End of 8 Weeks of Treatment</measure>
    <time_frame>After 8 weeks of treatment with the patch, outcome will be measured.</time_frame>
    <description>quit rate verified with carbon monoxide breath sample (abstinence: less than or equal to 10ppm)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Side Effects</measure>
    <time_frame>8 weeks</time_frame>
    <description>frequency of serious adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">87</enrollment>
  <condition>Nicotine Dependence</condition>
  <arm_group>
    <arm_group_label>21mg transdermal nicotine + placebo patch</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>21mg transdermal nicotine + placebo patch</description>
  </arm_group>
  <arm_group>
    <arm_group_label>42mg transdermal nicotine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>42mg transdermal nicotine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicoderm CQ transdermal nicotine</intervention_name>
    <description>Transdermal nicotine patch (21mg vs. 42mg), 8 weeks</description>
    <arm_group_label>21mg transdermal nicotine + placebo patch</arm_group_label>
    <arm_group_label>42mg transdermal nicotine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo patch</description>
    <arm_group_label>21mg transdermal nicotine + placebo patch</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females age 18-45 who smoke &gt; 10 cigarettes/ day;

          2. Able to communicate in English;

          3. Able to use NRT safely (e.g., no allergy to latex);

          4. Able to provide written informed consent for study procedures;

          5. Residing in the geographic area for at least 6 months; and

          6. A 3-HC/cotinine ratio in the top quartile of the distribution (Schnoll et al., 2008).
             Age 45 was selected as an upper limit to reduce the likelihood of adverse effects from
             high dose transdermal nicotine.

        Exclusion Criteria:

          1. History of substance abuse or currently receiving treatment for substance abuse (e.g.,
             alcohol, opioids, cocaine, marijuana);

          2. Current (last 6-months) alcohol consumption that exceeds 25 standard drinks/week.

          3. Current use or discontinuation within last 14 days of:

               -  Smoking cessation medications (bupropion, Chantix, NRT);

               -  Antipsychotics, atypicals, mood-stabilizers, anti-depressants (tricyclics, SSRIs,
                  MAOIs), anti-panic agents, anti-obsessive agents, anti-anxiety agents,
                  stimulants);

               -  Medication for pain;

               -  Anti-coagulants;

               -  Heart medications;

               -  Daily medication for asthma or diabetes.

          4. Women who are pregnant, planning a pregnancy, or lactating;

          5. History or current diagnosis of psychosis, major depression or bipolar disorder,
             psychotic disorder, or generalized anxiety disorder;

          6. Serious/unstable disease within the past 6 months (e.g., cancer [but melanoma],
             HIV/AIDS);

          7. History of epilepsy or seizure disorder;

          8. History or diagnosis within the last 6 months of abnormal rhythms and/or tachycardia
             (&gt;100 beats/minute); history or current diagnosis of COPD, cardiovascular disease
             (stroke, angina), heart attack in the last 6 months, uncontrolled hypertension
             (SBP&gt;150 or DBP&gt;90);

          9. History of kidney or liver failure.

         10. Any medical condition or medication that could compromise safety as determined by a
             study physician;

         11. Inability to provide informed consent or complete the study tasks as determined by the
             Principal Investigator or study physician.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert A Schnoll, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2009</study_first_submitted>
  <study_first_submitted_qc>August 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2009</study_first_posted>
  <results_first_submitted>January 14, 2013</results_first_submitted>
  <results_first_submitted_qc>February 14, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 18, 2013</results_first_posted>
  <last_update_submitted>August 12, 2014</last_update_submitted>
  <last_update_submitted_qc>August 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Robert Schnoll</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>nicotine dependence</keyword>
  <keyword>nicotine replacement therapy</keyword>
  <keyword>transdermal nicotine</keyword>
  <keyword>nicotine metabolism</keyword>
  <keyword>high dose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Media ads asked treatment-seeking smokers to call for information about a smoking cessation program and to have their initial eligibility reviewed. Participants interested in the clinical trial and initially eligible attended an in-person session to determine their final eligibility. Recruitment was from 2009-2011.</recruitment_details>
      <pre_assignment_details>To be eligible, participants had to be: between age 18 and 55, smoke &gt;10 cigarettes/day, and able to communicate in English. In addition, participants had to have a 3-HC/cotinine ratio that placed them in the top 3 quartiles of the 3-HC/cotinine ratio distribution to be consider fast nicotine metabolizers, which was &gt;.18.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>21mg Transdermal Nicotine + Placebo Patch</title>
          <description>21mg transdermal nicotine + placebo patch
Nicoderm CQ transdermal nicotine : Transdermal nicotine patch (21mg vs. 42mg), 8 weeks
placebo : placebo patch</description>
        </group>
        <group group_id="P2">
          <title>42mg Transdermal Nicotine</title>
          <description>42mg transdermal nicotine
Nicoderm CQ transdermal nicotine : Transdermal nicotine patch (21mg vs. 42mg), 8 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Baseline</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>21mg Transdermal Nicotine + Placebo Patch</title>
        </group>
        <group group_id="B2">
          <title>42mg Transdermal Nicotine</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="43"/>
            <count group_id="B2" value="44"/>
            <count group_id="B3" value="87"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.1" spread="9.0"/>
                    <measurement group_id="B2" value="38.8" spread="9.0"/>
                    <measurement group_id="B3" value="38" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Biochemically Verified 7-day Point Prevalence Abstinence at the End of 8 Weeks of Treatment</title>
        <description>quit rate verified with carbon monoxide breath sample (abstinence: less than or equal to 10ppm)</description>
        <time_frame>After 8 weeks of treatment with the patch, outcome will be measured.</time_frame>
        <population>intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>21mg Transdermal Nicotine + Placebo Patch</title>
            <description>21mg transdermal nicotine + placebo patch
Nicoderm CQ transdermal nicotine : Transdermal nicotine patch (21mg vs. 42mg), 8 weeks
placebo : placebo patch</description>
          </group>
          <group group_id="O2">
            <title>42mg Transdermal Nicotine</title>
            <description>42mg transdermal nicotine
Nicoderm CQ transdermal nicotine : Transdermal nicotine patch (21mg vs. 42mg), 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Biochemically Verified 7-day Point Prevalence Abstinence at the End of 8 Weeks of Treatment</title>
          <description>quit rate verified with carbon monoxide breath sample (abstinence: less than or equal to 10ppm)</description>
          <population>intent to treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side Effects</title>
        <description>frequency of serious adverse events</description>
        <time_frame>8 weeks</time_frame>
        <population>intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>21mg Transdermal Nicotine + Placebo Patch</title>
            <description>21mg transdermal nicotine + placebo patch
Nicoderm CQ transdermal nicotine : Transdermal nicotine patch (21mg vs. 42mg), 8 weeks
placebo : placebo patch</description>
          </group>
          <group group_id="O2">
            <title>42mg Transdermal Nicotine</title>
            <description>42mg transdermal nicotine
Nicoderm CQ transdermal nicotine : Transdermal nicotine patch (21mg vs. 42mg), 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Side Effects</title>
          <description>frequency of serious adverse events</description>
          <population>intent to treat</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>21mg Transdermal Nicotine + Placebo Patch</title>
          <description>21mg transdermal nicotine + placebo patch
Nicoderm CQ transdermal nicotine : Transdermal nicotine patch (21mg vs. 42mg), 8 weeks
placebo : placebo patch</description>
        </group>
        <group group_id="E2">
          <title>42mg Transdermal Nicotine</title>
          <description>42mg transdermal nicotine
Nicoderm CQ transdermal nicotine : Transdermal nicotine patch (21mg vs. 42mg), 8 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>influenze</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This was a proof of concept trial and, as such, was inadequately powered to detect statistically significant treatment arm effects and did not include a long-term follow-up assessment.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Robert A. Schnoll, Ph.D.</name_or_title>
      <organization>University of Pennsylvania</organization>
      <phone>215-746-7143</phone>
      <email>schnoll@mail.med.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

